Trial Profile
Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 17 Aug 2022
Price :
$35
*
At a glance
- Drugs Ivabradine (Primary)
- Indications Chronic heart failure
- Focus Therapeutic Use
- Acronyms FIRST
- Sponsors Jiangsu Hengrui Medicine Co.
- 09 Aug 2022 Results assessing role of ivabradine hemisulfate sustained release (SR), a novel long-acting formulation of ivabradine dosed once daily, in stable patients with HFrEF published in the Journal of the American College of Cardiology
- 25 Nov 2015 New trial record